Eli Lilly and Company (LLY)

Name: Eli Lilly and Company (LLY) — تاریخچه صورتهای مالی
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

تاریخچه درآمد، سود و جریان نقد از صورت‌های مالی رسمی.

Health Care · وال‌استریت (آمریکا) · آخرین به‌روزرسانی: 2026-08-07

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

شاخص‌های کلیدی

ارزش بازار: $1.02 trillion
درآمد (سال مالی منتهی به 2025-12-31): $65.2B
سود خالص: $20.6B
حاشیه سود ناخالص: 83.8%
حاشیه سود خالص: 31.7%

نمودارهای تعاملی و صورت‌های مالی کامل ← مدل ارزش‌گذاری (DCF) ←

صورت سود و زیان سالانه

صورت سود و زیان	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
مجموع درآمد	$79.7B	$65.2B	$45.0B	$34.1B	$28.5B	$28.3B	$24.5B	$22.3B	$21.5B	$20.0B	$21.2B	$20.0B	$19.6B	$23.1B	$22.6B	$24.3B	$23.1B	$21.8B	$20.4B	$18.6B	$15.7B
سود ناخالص	$66.9B	$54.6B	$36.6B	$27.0B	$21.9B	$21.0B	$19.1B	$17.6B	$16.8B	$15.5B	$15.5B	$14.9B	$14.7B	$18.2B	$17.8B	$19.2B	$18.7B	$17.6B	$16.0B	$14.4B	$12.1B
حاشیه سود ناخالص %	84.0%	83.8%	81.3%	79.2%	76.8%	74.2%	77.7%	78.8%	78.2%	77.7%	73.1%	74.8%	74.9%	78.8%	78.8%	79.1%	81.1%	80.5%	78.5%	77.2%	77.4%
سود عملیاتی (EBIT)	$35.0B	$29.7B	$17.5B	$10.8B	$8.7B	$7.9B	$7.2B	$6.0B	$6.0B	$4.2B	$3.9B	$3.6B	$3.3B	$5.5B	$5.0B	$6.3B	$6.8B	$6.4B	$5.5B	$4.8B	$4.1B
حاشیه سود عملیاتی %	43.9%	45.6%	38.9%	31.6%	30.3%	28.0%	29.4%	26.9%	28.0%	21.3%	18.2%	18.0%	17.0%	24.0%	22.2%	26.0%	29.3%	29.2%	27.1%	25.8%	26.3%
سود خالص	$26.7B	$20.6B	$10.6B	$5.2B	$6.2B	$5.6B	$6.2B	$8.3B	$3.2B	($204M)	$2.7B	$2.4B	$2.4B	$4.7B	$4.1B	$4.3B	$5.1B	$4.3B	($2.1B)	$3.0B	$2.7B
حاشیه سود خالص %	33.5%	31.7%	23.5%	15.4%	21.9%	19.7%	25.2%	37.3%	15.0%	-1.0%	12.9%	12.1%	12.2%	20.3%	18.1%	17.9%	22.0%	19.8%	-10.2%	15.8%	17.0%
EBITDA	$35.2B	$27.9B	$15.2B	$8.6B	$8.7B	$8.0B	$8.9B	$6.9B	$5.5B	$4.1B	$5.1B	$4.4B	$4.5B	$7.5B	$7.0B	$6.9B	$8.0B	$6.9B	$43M	$5.9B	$4.9B
سود هر سهم (EPS)	$29.80	$22.98	$11.71	$5.80	$6.57	$5.85	$6.47	$8.69	$3.13	$-0.19	$2.49	$2.18	$2.15	$4.19	$3.57	$3.90	$4.58	$3.94	$-1.89	$2.71	$2.45
سهام منتشرشده (میلیون)	894M	898M	904M	903M	950M	954M	957M	958M	1,034M	1,052M	1,101M	1,105M	1,111M	1,117M	1,146M	1,114M	1,106M	1,098M	1,094M	1,091M	1,087M

منبع: گزارش‌های عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.

ترازنامه‌ها، جریان‌های نقدی، داده‌های فصلی و نسبت‌های مالی کامل در نمایشگر تعاملی LLY در دسترس است. /companies/us/LLY

شرکت‌های مشابه

اطلاعات این وب‌سایت صرفاً برای اهداف آموزشی و اطلاع‌رسانی است و توصیه سرمایه‌گذاری نیست. هیچ هدف قیمتی یا توصیه‌ای منتشر نمی‌شود.

English version →همه سهام

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.